Assessment of targets of antibody drug conjugates in SCLC

Assessment of targets of antibody drug conjugates in SCLC

Abstract Antibody-drug conjugate (ADC) therapy has transformed treatment for several solid tumors, including small cell lung cancer (SCLC). However, significant challenges remain, including systemic toxicity, acquired resistance, and the lack of reliable biomarkers for patient selection. To enhance...

Full description

Saved in:
Bibliographic Details
Main Authors: Abhishek Ajay, Han Wang, Ali Rezvani, Omid Savari, Brandon J. Grubb, Karen S. McColl, Suzy Yoon, Peronne L. Joseph, Shelby R. Kopp, Adam M. Kresak, Craig D. Peacock, Gary M. Wildey, Minh Lam, Masaru Miyagi, Hung-Ying Kao, Afshin Dowlati
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-024-00784-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41698-024-00784-7

Similar Items